Amgen (AMGN) Tops Q2 EPS by 26c, Offers Guidance

Amgen (NASDAQ: AMGN) reported Q2 EPS of $4.65, $0.26 better than the analyst estimate of $4.39. Revenue for the quarter came in at $6.59 billion versus the consensus estimate of $6.53 billion.

GUIDANCE:

Amgen sees FY2022 EPS of $17.00-$18.00, versus the consensus of $17.40. Amgen sees FY2022 revenue of $25.5-26.4 billion, versus the consensus of $26.23 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c
• Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c